Lindstrm, E., Eliasson, L., Bjrkqvist, and Hkanson, R
peripheral nerve motor or sensory loss, Guillaine Barre type syndrome, multiple cranial nerve palsies Immune related adverse events (IrAE) occur in up to 90% patients administered ipilimumab up to 70% patients administered PD1/PDL1 inhibitors (pembrolizumab, nivolumab, atezolizumab) First line pembrolizumab (PD1) in lung cancer 1 in 10 had a G3 or G4 toxicity (better than chemotherapy) 1 in 20 stopped treatment due to toxicity These are very rarely immunosuppressive drugs sick patients are unlikely to have neutropenic sepsis mainstay of treatment of immune related adverse events - STEROIDS Immune Related Adverse Events: Primary care need to be aware that side effects may not be immediate: onset of these toxicities varies but usually starts within the first 8 to 12 weeks of initiation of treatment Reference: Brooks M, Olsson-Brown A
Transl Sci
Platelet activation, aggregation, and subsequent intra-arterial thrombosis are important steps in atherosclerotic thrombosis, and enhanced platelet reactivity is associated with the degree of terminal organ injury and poor prognosis (73)
BioActive delivers 3 most beneficial forms of Vitamin B12: Methylcobalamin, Adenosylcobalamin, and Hydroxocobalamin
